Samsung Bioepis announced that the FDA accepted a biologics license application for SB8, a biosimilar candidate for bevacizumab.
Myovant announced that their phase III HERO study of relugolix met its primary efficacy end point and all 6 secondary endpoints in men with advanced prostate cancer.
Fewer biopsies among men receiving antidiabetic medications may explain the lower prostate cancer risk in men with diabetes.
Marjorie Zauderer, MD, from Memorial Sloan Kettering Cancer Center, discussed new immunotherapy approaches at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
The FDA granted accelerated approval to zanubrutinib for the treatment of adult patients with MCL who have received at least 1 prior therapy.
Luca Biavati, MD, from Johns Hopkins Medicine, discussed bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Geriatric assessments have now been recommended as part of the standard evaluation of
an older adult considering cancer therapy.
Burnout is defined as an occupational-related syndrome characterized by physical and emotional exhaustion, cynicism/depersonalization, and low sense of professional accomplishment.
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib.